Nervous Disorder TRIZ Cases

Truncated tau protease variants break down disease-causing proteins to halt Alzheimer's progression.

Targeting miR-204 with antisense oligonucleotides restores NMDA receptor expression and dendritic spine density, addressing age-related cognitive decline.

Alpha-1-antitrypsin inhibits elastase activity and prevents RNase L degradation, reducing inflammation in chronic fatigue syndrome.

DLL4 antagonist antibodies block Notch signaling to expand regulatory T cells, treating multiple sclerosis and type 1 diabetes by modulating immune homeostasis.

Low-dose interleukin-2 selectively amplifies regulatory T cells to treat neurodegenerative conditions.

Pivaloyloxymethyl and propyloxycarbonyloxymethyl ester modifications enable effective oral administration of the potent PSMA inhibitor 2-PMPA.

Late passage hMSCs differentiate into glia-like cells to restore growth factor secretion and reduce infarct volume.

A histone acetyltransferase inhibitor competes with acetyl-CoA for the catalytic active site of p300/CBP.

Controlled precipitation yields stable cyclo-(Arg-Gly-Asp-DPhe-NMe-Val) crystals, resolving amorphous hygroscopicity and polymorphic instability.

A tablet formulation using low-density crystalline cellulose, sugar alcohol, and pregelatinized starch for rapid oral disintegration.

A human naïve antibody library generated using combined phage and yeast surface display technologies for high-affinity selection.

Young donor exosomes alleviate brain injury by inhibiting ferroptosis, offering a targeted therapy with no organ toxicity.

Cyclic peptides targeting SorCS1-3 receptors activate CREB and clear misfolded proteins, addressing insufficient neurodegenerative disease treatments.

Hydrophobic peptide domains form supramolecular nanofibers that retain sodium channel blockers, preventing rapid diffusion and overdose risks.

Chopping 3D organoids enriches stem cells to produce midbrain-type neural stem cells and astrocytes.

Standardized sesamol-peptide conjugates resolve manufacturing variability by boosting enzyme activity for consistent hangover relief.

Segmenting glial cell line-derived neurotrophic factor into amidated peptides resolves limited bioavailability and distribution constraints.

A triglyceride composed mainly of pentadecanoic acid inhibits endoplasmic reticulum stress in neurons.

Ramalin targets upstream inflammatory mediators to suppress amyloidogenic pathways, addressing neuronal loss in neurodegenerative disease models.

Peptoid 1 mimics LL-37 to inhibit Aβ amyloid formation while crossing the blood-brain barrier, addressing proteolytic instability and neuroinflammation.

Encapsulated interleukin 12 in a semi-crystalline matrix overcomes systemic toxicity and cold tumor resistance by sustaining local release.

Spirulina extracts extend intestinal absorption time for curcumin, reducing rapid elimination and gastrointestinal irritation.

Intranasal administration of GCP-II inhibitors bypasses the blood-brain barrier, achieving therapeutic brain concentrations while reducing systemic exposure.

A fixed-ratio formulation of vitamins A and D with DHA and EPA lowers IL-6 release from activated microglia while minimizing dosage complexity.

Sultiame reduces apneic events and daytime sleepiness while avoiding paraesthesia common with zonisamide.

Breathable containers release volatile oils while magnetic beads stimulate blood flow to treat hypoxic lesions.

Reducing water to 26-45% weight transforms slurry into a soft paste, cutting processing time and energy consumption.

Freezing and thawing adipose tissue isolates stem cells without red blood cell lysis buffers, enabling direct CNS administration that slows disease progression.

Oligonucleotide decoys inhibit pain-related gene expression via complementary base pairing, resolving toxicity trade-offs in chronic pain treatment.

Humanized anti-EphA4 antibody blocks EphA4-ligand binding, addressing insufficient therapeutic effectiveness in neurodegenerative disease treatment.

Nanoligomers downregulate NLRP3 and NF-κβ to reduce neuroinflammation in neurodegenerative diseases.

Specific amino acid mutations at positions 11, 89, 110, and 112 minimize binding with pre-existing antibodies while maintaining therapeutic efficacy.

Stearoyl amino acid salt overcomes low solubility and poor bioavailability of the parent compound by converting it into an ionic form via alkaline hydrolysis.

A lipid composition combining medium chain triglycerides, soy lecithin, biotin, and antioxidants to support neurological function.

Phosphorylated peptides inhibit crystallization of amorphous calcium carbonate, maintaining stability for pharmaceutical applications.

Modified lixisenatide crosses the blood-brain barrier to reduce amyloid plaque load and improve neuronal survival in neurodegenerative disease treatment.

40 mg inorganic nitrite formulations maintain nitric oxide levels to alleviate neuropathic pain without inducing chronic ischemia.

Covalent linking of alpha-galactosidase monomers extends plasma half-life beyond ten days, reducing treatment frequency for Fabry disease.

A composite digestive enzyme preparation alleviates delayed onset muscle soreness by addressing absorption issues that limit single-enzyme treatments.

Pyridoxamine combined with thiamine improves ASD symptoms while preventing vitamin B1 deficiency caused by high-dose pyridoxine.

A ketone body-HMB composition promotes simultaneous muscle building and fat loss.

Rapastinel treats alcohol dependence by inhibiting NMDA receptor upregulation, reducing side effects compared to existing medications.

Modified AAV capsid proteins enable efficient microglia targeting via specific amino acid insertions in the binding arm region.